NCT01796795

Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients

A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.

• Status: Suspended
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 102 (estimated)
• Sponsor: G&E Herbal Biotechnology Co., LTD · Industry
• Sex: All
• Age: 17 Years
• Healthy volunteers: Not accepted

Summary

This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.

Conditions

• Common Wart

Interventions

Type	Name	Description
DRUG	Vehicle gel	Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
DRUG	SR-T100 gel with 1.0% of SM	Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
DRUG	SR-T100 gel with 2.3% of SM	Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.

Timeline

• Start date: 2030-09-01
• Primary completion: 2033-04-01
• Completion: 2033-08-01
• First posted: 2013-02-22
• Last updated: 2023-09-14

Regulatory

• FDA-regulated drug study